Title: An Open Label Prospective Study to Evaluate the Efficacy of Entecavir in HBeAg Positive Treatment Naive Chronic Hepatitis –B Patients in A Tertiary Care Centre in Eastern India
Authors: Manjushree Nayak, JayantaKumar Panda, Umesh Chandra Patra
DOI: https://dx.doi.org/10.18535/jmscr/v5i6.02
Abstract
Background: Entecavir is a nucleoside analogue drug that has selective anti-hepatitis B virus (HBV) activity. It is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication, persistent elevations in serum aminotransferase and histologically active disease. We conducted a study to evaluate the efficacy of entecavir (ETV) in hepatitis Beantigen (HBeAg) positive- chronic hepatitis B (CHB) treatment naive Indian patients in real life scenario.
Method: This is a single center open label prospective observational study to evaluate the efficacy of Entecavir in chronic hepatitis B patients. A total of 140 patients were enrolled in the study from January 2015 to December 2016. Parameters were evaluated at baseline and at 12, 24 and 40 weeks of the treatment, Efficacy of entecavir was assessed by evaluating hepatitis B virus DNA (HBV DNA), serum alanine aminotransferase (ALT) and sero-conversion.
Result: The mean HBV DNA at baseline was 5.99 log [on a base-10 scale] IU/mL which decreased to 2.12 log IU/mL at the end of 40 weeks. Thus there was a mean change of 3.87 log IU/ml which was statistically significant (P<0.0001). Out of 140 HBeAg positive subjects, 50 (35.71 %) had become negative at the end of 40 weeks. Only 10.71% of the patients had normal ALT (<40IU/l) values in the beginning which increased to 100% at the end of 40 weeks.
Conclusion: Entecavir significantly improves virological, biochemical and serological markers in HBeAg positive treatment naïve chronic hepatitis B patients.
Keywords: Chronic hepatitis B, Entecavir, (ETV) HBV DNA.
References
1. 1. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007 Nov;133(5):1437-44.
2. Choudary A.Santra A Chakravorty A, Banarji A,Pal S, Dhali G K, et al Community-based epidemiology of hepatitis B virus infection in West Bengal, India: Prevalence of hepatitis B e antigen-negative infection and associated viral variants Journal of Gastroenterology and Hepatology November 2005.
3. Lai CL, Yuen MF Chronic hepatitis B- New goals, new treatment. N Engl J Med. 2008 Dec 4;359(23):2488-91.
4. Yang MF, Yuan HJ, Wong DK, Yuen JC, WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asian: therapeutic implications. Gut. 2005;54:1610-4.
5. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al Taiwan community –based cancer screening project group. Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Ned. 200218;347(3):168-74.
6. Perrillo RP, Marcellin P Effect of newer oral antiviral agents on future therapy of chronic hepatitis B, Antivir Ther. 2010;15(1):13-22.
7. De Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection Hepatology. 2001 Sep;34(3):578-82.
8. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, O’Brien C, Tamburro C, Jacobson IM, et al A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group N Engl J Med. 1990 Aug 2;323 (5): 295 -30
9. Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Jiang Z, Liu J, Xu D, macdonald L; for the AI463023 Study Group Efficacy and safety of entecavir compared to lamivudine in nucleoside –naïve patients with chronic hepatitis B: a randomized double-blind trial in ChinaHepato Int. 2008Mar;2(1):136.
10. Colonno RJ, Rose R Baldick CJ, Levine S, Pokornowski k, Yu CF, Walsh Entecavir resistance is rare in nucleoside naïve patients with hepatitis b Hepatology. 2006 Dec;44(6):1656-65.
11. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al Early Hepatitis B virus DNA Reduction in Hepatitis B e Antigen-positive Patients with Chronic Hepatitis B: A Randomized International Study of Entecavir Versus Adefovir Hepatology. 2009 Jan;49(1):72-9.
12. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC A comparison of entecavir and lamivudine for HBeAg-Positive chronic hepatitis B N Engl J Med. 2006 Mar 9;354(10):1001-10.
13. Ren FY, Piao XX, A one-year trial of ETV in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007 : 13 (31): 4264-4267.
14. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J,et al Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009 May;49(5):1503-14.
15. Lok AS, McMahon BJ; AASLD (American Association for the Study of Liver Disease). Chronic Hepatitis B: Update 2009 Hepatology 2009.
16. Bihl F, Alaei M, Negro F. The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians. Swiss Wkly. 2010 Mar 20;140(11-12):154-9.
17. Ren FY, Piao DM, Piao XX. A one-year trial of ETV in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13(31):4264-4267.
18. Sherman M. Yardaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis b Liver Disease (BEHOLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008 Jul;48(1):99-108.
19. Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, Chen CW. Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naïve chronic hepatitis B patients Zhonghua Gan Zang Bing Za Zhi. 2009 Dec;17(12):881-6.